Company news: ViroPharma and DIME

Share this article:

Specialty drug company ViroPharma teamed with several medical societies on the launch of a program designed to unite specialists treating patients with the orphan condition hereditary angioedema (HAE). The main component of the program—called HAE: Learn About It, Talk About It—is the website LetsTalkHAE.com, which offers tools designed to readily diagnose and properly manage patients with the rare, potentially fatal swelling disorder. A joint effort initially targeting allergists and gastroenterologists, the program has grown to include NPs, PAs and emergency physicians. ViroPharma markets HAE therapy Cinryze.

Accredited med ed provider DIME launched a web browser designed to facilitate internet searching-and-learning, in which clinicians hunt online for answers to clinical questions in exchange for credit. The tool, called iPointOfCare, integrates across all browsers and devices and is optimized for the mobile environment, DIME said. About 116,000 physicians participated in this form of education in 2009, according to the ACCME.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.